Membro del progetto di A3-year open label, non comparative extension to a randomized, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (20 to 60 mg/kg/day) in Beta-thalassemia patients with transfusional hemosiderosis(2004 Jan).
Membro del progetto di A3-year open label, non comparative extension to a randomized, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (20 to 60 mg/kg/day) in Beta-thalassemia patients with transfusional hemosiderosis
2004
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.